Systemic lupus erythematosus - Diagnosis and Laboratory Evaluation

Diagnosis of Systemic Lupus Erythematosus Introduction Diagnosing lupus presents a clinical challenge because no single test is both completely sensitive and specific for the disease. Instead, diagnosis relies on a combination of clinical features and laboratory findings organized into standardized classification criteria. Understanding both the individual laboratory tests and how they fit together in the diagnostic framework is essential for recognizing lupus in clinical practice. Laboratory Testing: The ANA and Beyond Antinuclear Antibody Testing The antinuclear antibody (ANA) test using indirect immunofluorescence is the cornerstone of lupus workup. It is highly sensitive, meaning it catches most lupus patients—a positive ANA is present in approximately 95-98% of people with lupus. However, it is not specific, meaning many people without lupus also test positive. This is why a positive ANA alone cannot diagnose lupus; you must combine it with clinical features and other laboratory findings. Think of the ANA as a screening tool that helps you say "this could be lupus" rather than a confirmatory test that says "this definitely is lupus." Disease-Specific Antibodies When an ANA is positive, looking for more specific antibodies helps narrow the diagnosis. Several antibodies have particular importance in lupus: Anti-Smith (anti-Sm) antibodies are highly specific for lupus, meaning if present, lupus is very likely. However, they appear in only about 20-30% of lupus patients, so a negative result doesn't rule out the disease. Anti-U1 RNP antibodies are associated with lupus but can also appear in other autoimmune diseases like mixed connective tissue disease. Anti-SSA (Ro) and anti-SSB (La) antibodies are typically associated with lupus, particularly the cutaneous form, though they also appear in Sjögren syndrome. The key principle: these specific antibodies help confirm lupus when present, but their absence doesn't exclude the diagnosis. Classification Criteria: The ACR Standards How the Criteria Work Since no single test confirms lupus, the American College of Rheumatology (ACR) established classification criteria in 1997 (revised from original 1982 criteria) to provide a standardized way to identify lupus patients, particularly for research studies. These criteria have become the clinical standard for diagnosis as well. The criteria are simple in principle: a patient is classified as having lupus if they meet at least 4 of the 11 items, either all at once or at different times. This means you need multiple pieces of evidence pointing toward lupus. The Eleven Criteria Items The 11 items are organized into clinical and immunologic categories: Clinical Features: Malar rash — the classic "butterfly" rash across the cheeks and nose Discoid rash — round, scarring skin lesions, typically on the scalp, face, or ears Photosensitivity — an exaggerated skin reaction to sun exposure Oral ulcers — usually painless ulcers in the mouth Serositis — inflammation of the membranes surrounding the heart (pericarditis) or lungs (pleuritis) Non-erosive arthritis — joint swelling and pain in at least two peripheral joints, without permanent bone damage Renal disorder — either significant protein in the urine (proteinuria) or cellular casts indicating kidney inflammation Hematologic Disorder — any of the following: Hemolytic anemia, leukopenia (low white blood cells), lymphopenia (low lymphocytes), or thrombocytopenia (low platelets) Immunologic Findings: Positive antinuclear antibody test — by standard immunofluorescence Immunologic disorder — presence of anti-Smith antibodies, anti-double-stranded DNA (anti-dsDNA) antibodies, antiphospholipid antibodies, or a false-positive syphilis test Neurologic disorder — seizures or psychosis without other explanation (note: this appears in some versions of the criteria) The flexibility of this system—meeting criteria at different times or all at once—accounts for lupus's fluctuating nature. Laboratory Markers: Complement and Anti-DNA Antibodies Complement C3 Levels Low serum levels of complement C3 (and sometimes C4) are important markers in lupus. Complement is a system of proteins that help fight infections and clear damaged cells. In lupus, the immune system consumes complement as it damages various tissues, causing levels to drop. When you find both low C3 levels and anti-double-stranded DNA (anti-dsDNA) antibodies together, this combination is particularly useful for both diagnosing lupus and classifying disease severity. These findings suggest active immune activity and are often associated with more active disease, particularly kidney involvement. Anti-Double-Stranded DNA Antibodies Anti-dsDNA antibodies are highly specific for lupus (though less common than ANA positivity). These antibodies attack the cell's own genetic material, which is why they correlate with more systemic manifestations, particularly lupus nephritis. The presence and level of anti-dsDNA antibodies can help predict disease flares and progression. <extrainfo> Additional Diagnostic Tests Lupus Band Test The lupus band test involves taking a skin biopsy from a lupus patient and staining it to detect deposits of immunoglobulin and complement proteins at the dermal-epidermal junction (the boundary between skin layers). While this test can support a lupus diagnosis, it is less commonly used than blood-based tests because it requires a biopsy and is primarily confirmatory rather than screening. 2019 EULAR/ACR Revised Classification Criteria In 2019, the European League Against Rheumatism and American College of Rheumatology updated the classification criteria using a weighted scoring system that emphasizes certain clinical and immunologic features based on their predictive value for lupus. While this newer system is increasingly used in clinical practice, the 1997 ACR criteria remain widely recognized and may still be referenced on exams. The newer criteria aim to better identify lupus cases while reducing false positives. </extrainfo>